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INTRODUCTION 
Epilepsy is a neurological disorder characterized by recurrent 
seizures and affects approximately 1% of Canadians [1]. 
While treatment with medications is often effective, 40% of 
the 300 000 Canadians suffering from epilepsy are refractory 
to medications. Furthermore, only 5% of patients with 
refractory epilepsy respond clinically to additional 
antiepileptic drug (AED) [2]. This group of patients is referred 
to the Calgary Epilepsy Program (CEP). To clarify diagnoses, 
optimize therapy or for pre-surgical evaluation, they are 
subsequently admitted to the Seizure Monitoring Unit (SMU) 
for on average 8 days. However, over a fifth (21%) of SMU 
patients do not have seizure events while on the unit. The 
purpose of this study was first to develop an electronic 
database for SMU patients and then to utilize patient data to 
predict the likelihood of their seizure events on the SMU.  
METHODS 
SMU Admission/Discharge summary forms were created in 
REDCap, an electronic survey builder. Assessed variables 
include: demographics, reason for referral, seizure frequency 
and type, type of medications, procedures performed and tests 
ordered. Multiple quality of life and depression scales, 
including: AEP, Bacca Scale, EQ-5D-3L, GADS, GASE, 
NDDI-E, PANAS, PHQ-9, QOLIE-31 and TSQM-II were 
added for future data collection. 
Patient admission data (n=603) from 2008 to 2014 was 
analyzed using chi-squared test and Student’s t-test. Patient 
characteristics, including: age, number of AEDs, seizure 
frequency and psychotropic medications before admission 
were compared between those that had seizure events and 
those that did not have seizure events on the unit. Data was 
analyzed on iPython Notebook. 
RESULTS 
Patients with seizure events (n=474) had more AEDs (1.9 ± 
1.1 vs 1.6 ± 1.1, p < 0.01), a higher seizure frequency (Daily 
vs Weekly, p < 0.05) or were less likely to be on psychotropic 
medications (26.5% vs 44.5%, p < 0.001) before admission. 
There is no statistically significant correlation between age 
and the occurrence of seizure events (Table 1).  
Patient 
characteristic  
before admission 
Seizure events 
(78.6%, n= 474) 
No seizure event 
(21.2%, n=128) p 
Age  
(Mean ± SD) 36.6 ± 13.5  37.8 ± 13.5 > 0.05 
Number of AEDs  
(Mean ± SD) ** 1.9 ± 1.1 1.6 ± 1.1 < 0.01 
Seizure frequency 
(Mode) * Daily Weekly < 0.05 
Psychotropic 
medications 
(% Yes) *** 26.6 44.5 
< 
0.001 
 
Table 1. Comparison of pre-admission patient characteristics 
between those with and without seizure events. Sample size 
n=603. Statistical tests: chi-squared for non-parametric 
variables and Student’s t-test for parametric variables. 
 
DISCUSSION AND CONCLUSIONS 
CEP and SMU patient data can now be accessed through a 
single electronic database to facilitate epilepsy research and 
patient care. The database linking patient admission data to 
measurements of patient quality of life, depression and 
satisfaction will give researchers better insight into treatment 
outcomes for patients with epilepsy.  
 
The probability of having a seizure event on the SMU is 
higher with a higher number of antiepileptic drugs (p < 0.01), 
higher seizure frequency (p < 0.05) or lower number of 
psychotropic medications (p < 0.001) before admission. The 
use of pre-admission variables to predict the likelihood of 
seizure events on the SMU will help improve referral accuracy 
and reduce unnecessary hospitalization which costs several 
thousand dollars daily. Continued analysis of other variables 
includes seizure type, primary reason for referral, type of AED 
and type of psychotropic medication.  
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